Search results for: Economics of Innovation

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

1 June 2019

Cada vez más, los avances científicos desarrollan nuevas medicinas que permiten mejoras en la supervivencia y calidad de vida para diversas indicaciones terapéuticas. La fijación de precios en función de…

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

1 January 2020

In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct…

Indication-Based Pricing (IBP) Consultation Report

1 April 2020

…countries representeda range of stakeholders including industry, payers, regulators and academics. The majority of respondents believed some form of IBP would be a good thing, but relative support varied between…

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

1 June 2020

…the OECD-average of 2.4% of Gross Domestic Product (GDP) by 2027, with a longer-term goal of reaching 3% to put the UK in the upper quartile. Whilst there is universal…

Value, Affordability, and Decision Making

Efficient decisions about the allocation of health care budgets require the assessment of the effects of health care interventions and of the value for money that they provide. Decision-making processes…

Lotte Steuten

8 January 2019

…Visiting Honorary Professor at City University of London, a member of the ISPOR Board of Directors and associate editor at Value in Health. She has published >100 peer-reviewed papers. Lotte’s…

Insights From 2022 and Emerging Issues in 2023

7 December 2022, 12:00am

…of health outcomes and where we have got to in including carers’ quality of life in Health Technology evaluations. Innovation, precision and value: Showcasing OHE’s indication-based payment masterclass and demonstrating…